These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 25790979)

  • 1. PD-L1 Upregulation Drives Escape from Anti-CTLA4 and Radiation Therapy.
    Cancer Discov; 2015 May; 5(5):OF13. PubMed ID: 25790979
    [No Abstract]   [Full Text] [Related]  

  • 2. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer.
    Twyman-Saint Victor C; Rech AJ; Maity A; Rengan R; Pauken KE; Stelekati E; Benci JL; Xu B; Dada H; Odorizzi PM; Herati RS; Mansfield KD; Patsch D; Amaravadi RK; Schuchter LM; Ishwaran H; Mick R; Pryma DA; Xu X; Feldman MD; Gangadhar TC; Hahn SM; Wherry EJ; Vonderheide RH; Minn AJ
    Nature; 2015 Apr; 520(7547):373-7. PubMed ID: 25754329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiotherapy complements immune checkpoint blockade.
    Ngiow SF; McArthur GA; Smyth MJ
    Cancer Cell; 2015 Apr; 27(4):437-8. PubMed ID: 25873170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy: A triple blow for cancer.
    Leavy O
    Nat Rev Cancer; 2015 May; 15(5):258-9. PubMed ID: 25833214
    [No Abstract]   [Full Text] [Related]  

  • 5. Tumour immunology: A triple blow for cancer.
    Leavy O
    Nat Rev Immunol; 2015 May; 15(5):265. PubMed ID: 25814401
    [No Abstract]   [Full Text] [Related]  

  • 6. Immunotherapy: Combined immunoradiotherapy reinvigorates antitumour immunity.
    Killock D
    Nat Rev Clin Oncol; 2015 Jun; 12(6):311. PubMed ID: 25801818
    [No Abstract]   [Full Text] [Related]  

  • 7. Radiotherapy and immune checkpoint blockade: potential interactions and future directions.
    Binder DC; Fu YX; Weichselbaum RR
    Trends Mol Med; 2015 Aug; 21(8):463-5. PubMed ID: 26091823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The benefits of immunotherapy combinations.
    Schmidt C
    Nature; 2017 Dec; 552(7685):S67-S69. PubMed ID: 29293245
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunotherapy and Checkpoint Inhibitors in Recurrent and Metastatic Head and Neck Cancer.
    Hashemi-Sadraei N; Sikora AG; Brizel DM
    Am Soc Clin Oncol Educ Book; 2016; 35():e277-82. PubMed ID: 27249733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining forces: the promise and peril of synergistic immune checkpoint blockade and targeted therapy in metastatic melanoma.
    Hermel DJ; Ott PA
    Cancer Metastasis Rev; 2017 Mar; 36(1):43-50. PubMed ID: 28181070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitors of Cytotoxic T Lymphocyte Antigen 4 and Programmed Death 1/Programmed Death 1 Ligand for Metastatic Melanoma, Dual Versus Monotherapy-Summary of Advances and Future Directions for Studying These Drugs.
    Loo K; Daud AI
    Cancer J; 2017; 23(1):3-9. PubMed ID: 28114249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in the Immunobiological Therapies for Advanced Melanoma.
    Pérez Gago MC; Saavedra Santa Gadea O; de la Cruz-Merino L
    Actas Dermosifiliogr; 2017 Oct; 108(8):721-728. PubMed ID: 28388991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Immunologic Approaches to Melanoma Treatment.
    Escandell I; Martín JM; Jordá E
    Actas Dermosifiliogr; 2017 Oct; 108(8):708-720. PubMed ID: 28527857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade.
    Saha D; Martuza RL; Rabkin SD
    Cancer Cell; 2017 Aug; 32(2):253-267.e5. PubMed ID: 28810147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Checkpoint Immunotherapy: Picking a Winner.
    Teng MW; Khanna R; Smyth MJ
    Cancer Discov; 2016 Aug; 6(8):818-20. PubMed ID: 27485001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Immune-checkpoints: the new anti-cancer immunotherapies].
    Ileana E; Champiat S; Soria JC
    Bull Cancer; 2013 Jun; 100(6):601-10. PubMed ID: 23735730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade.
    Benci JL; Xu B; Qiu Y; Wu TJ; Dada H; Twyman-Saint Victor C; Cucolo L; Lee DSM; Pauken KE; Huang AC; Gangadhar TC; Amaravadi RK; Schuchter LM; Feldman MD; Ishwaran H; Vonderheide RH; Maity A; Wherry EJ; Minn AJ
    Cell; 2016 Dec; 167(6):1540-1554.e12. PubMed ID: 27912061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1 and immune escape: insights from melanoma and other lineage-unrelated malignancies.
    Frydenlund N; Mahalingam M
    Hum Pathol; 2017 Aug; 66():13-33. PubMed ID: 28694003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The "immune checkpoints", how does it work].
    Granier C; Soumelis V; Mandavit M; Gibault L; Belazzoug R; de Guillebon E; Badoual C; Tartour E; Roussel H
    Ann Pathol; 2017 Feb; 37(1):18-28. PubMed ID: 28160999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.